Obtaining FDA approval for a product doesn't mean a company can rest on its laurels. In many cases, the work is really just beginning said Veracyte's (South San Francisco) President/CEO Bonnie Anderson. After approval comes the process of compiling a compelling body of post market data to help drive adoption rates. Nearly four years after obtaining FDA approval for the Afirma gene expression classifer (GEC), a test that is able to identify patients, whose thyroid nodules are noncancerous, Veracyte is in the process of garnering data. Read More
